Manipulating neuroinflammatory reactions in the injured spinal cord: Back to basics

Trends in Pharmacological Sciences

Volumn 24, Issue 1, 2003, Pages 13-17

  Popovich, Phillip G ^a   Jones, T Bucky ^a  

^a Immunology and Medical Genetics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CONVALESCENCE; IMMUNE FUNCTION TEST; INFLAMMATION; MEDIATOR; MITOSIS; MOLECULE; NEUROLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; TISSUE INJURY; TISSUE REGENERATION;

ANIMALS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; NEUROIMMUNOMODULATION; SPINAL CORD INJURIES;

EID: 0037216605     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)00006-8     Document Type: Article

References (50)

1. Schwartz M., et al. The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair. J. Mol. Med. 77:1999;713-717.
2. Rapalino O., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4:1998;814-821.
3. Schwartz M., Kipnis J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol. Med. 7:2001;252-258.
4. Perry V.H., et al. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J. Exp. Med. 165:1987;1218-1223.
5. Andersson P.B., et al. The kinetics and morphological characteristics of the macrophage-microglial response to kainic acid-induced neuronal degeneration. Neuroscience. 42:1991;201-214.
6. Lazarov-Spiegler O., et al. Restricted inflammatory response in the CNS: a key impediment to axonal regeneration? Mol. Med. Today. 4:1998;337-342.
7. Dusart I., Schwab M.E. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 6:1994;712-724.
8. Popovich P.G., et al. The cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377:1997;443-464.
9. Zhang Z., et al. Experimental analysis of progressive necrosis after spinal cord trauma in the rat: etiological role of the inflammatory response. Exp. Neurol. 143:1997;141-152.
10. Schnell L., et al. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 11:1999;3648-3658.
11. Popovich P.G. Inflammation and repair of the injured spinal cord: lessons from peripheral wound healing and evolution. Bondy S.C., Campbell A. Inflammatory Events in Neurodegeneration. 2001;276-290.
12. Nguyen M.D., et al. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat. Rev. Neurosci. 3:2002;216-227.
13. Fitch M.T., et al. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci. 19:1999;8182-8198.
14. Popovich P.G., et al. The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J. Neuropathol. Exp. Neurol. 61:2002;623-633.
15. Lehnardt S., et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 22:2002;2478-2486.
16. Taoka Y., et al. Role of neutrophils in spinal cord injury in the rat. Neuroscience. 79:1997;1177-1182.
17. Taoka Y., et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J. Neurosci. 18:1998;1393-1398.
18. Giulian D., et al. Reactive mononuclear phagocytes release neurotoxins after ischemic and traumatic injury to the central nervous system. J. Neurosci. Res. 36:1993;681-693.
19. Blight A.R. Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience. 60:1994;263-273.
20. Giulian D., Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann. Neurol. 27:1990;33-42.
21. Popovich P.G., et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp. Neurol. 158:1999;351-365.
22. Mabon P.J., et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166:2000;52-64.
23. Li M., et al. An essential role of the NF-κB/toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166:2001;7128-7135.
24. Guth L., et al. Spinal cord injury in the rat: treatment with bacterial lipopolysaccharide and indomethacin enhances cellular repair and locomotor function. Exp. Neurol. 126:1994;76-87.
25. Guth L., et al. Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury. Proc. Natl Acad. Sci. USA. 91:1994;12308-12312.
26. Johnston J.B., et al. Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann. Neurol. 50:2001;434-442.
27. Pette M., et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology. 40:1990;1770-1776.
28. Martin R., et al. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
29. Popovich P.G., et al. Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. J. Neurosci. Res. 45:1996;349-363.
30. Jones T.B., et al. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 22:2002;2690-2700.
31. Olsson T., et al. Facial nerve transection causes expansion of myelin autoreactive T cells in regional lymph nodes and T cell homing to the facial nucleus. Autoimmunity. 13:1992;117-126.
32. Olsson T. Autoreactive T and B cell responses to myelin antigens after diagnostic sural nerve biopsy. J. Neurol. Sci. 117:1993;130-139.
33. Kil K., et al. T-cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J. Neuroimmunol. 98:1999;201-207.
34. Wang W.Z., et al. Myelin antigen reactive T cells in cerebrovascular diseases. Clin. Exp. Immunol. 88:1992;157-162.
35. Becker K.J., et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc. Natl Acad. Sci. USA. 94:1997;10873-10878.
36. Bauer J., et al. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am. J. Pathol. 153:1998;715-724.
37. Hauben E., et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20:2000;6421-6430.
38. Hauben E., et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108:2001;591-599.
39. Moalem G., et al. Production of neurotrophins by activated T-cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15:2000;331-345.
40. Moalem G., et al. Autoimmune T-cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5:1999;49-55.
41. Koller H., et al. Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS. Prog. Neurobiol. 52:1997;1-26.
42. Hayes K.C., et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma. 19:2002;753-761.
43. Olivares-Villagomez D., et al. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 188:1998;1883-1894.
44. Shevach E.M. CD4+CD25+ suppressor T-cells: more questions than answers. Nat. Immunol. Rev. 2:2002;389-400.
45. Hammarberg H., et al. Neuroprotection by Encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci. 20:2000;5283-5291.
46. Serpe C.J., et al. Exacerbation of facial motorneuron loss after facial nerve transaction in severe combined immunodeficient (scid) mice. J. Neurosci. RC7:1999;1-5.
47. Muhallab S., et al. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T-cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand. J. Immunol. 55:2002;264-273.
48. Bielekova B., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:2000;1167-1175.
49. Kappos L., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 6:2000;1176-1182.
50. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 415:2002;462.